The fact that SHP agonism was effective in reducing the liver fibrosis in the ANIT model, while required CDCA in the CCl4 model, is likely due to different pathogenic mechanisms involved in the two models and fibrosis severity. The gene discussed is NR0B2; the disease is Hepatic fibrosis.